KORIAN (KORI.PA)

FR0010386334 - Common Stock

7.435  -0.02 (-0.27%)


Fundamental Rating

2

Taking everything into account, KORI scores 2 out of 10 in our fundamental rating. KORI was compared to 8 industry peers in the Health Care Providers & Services industry. KORI has a bad profitability rating. Also its financial health evaluation is rather negative. KORI has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

1

KORI has a Piotroski-F score of 5.00. This indicates an average health and profitability for KORI.
KORI's Return On Assets of 0.15% is worse than the rest of the industry. The industry average Return On Assets is 2.80%. 100% of the industry peers have a better Return On Assets.

KORI has a Return On Equity of 0.62%. This is below the industry average of 6.36%. 100% of the industry peers outperform KORI.
KORI's Profit Margin of 0.50% is worse than the rest of the industry. The industry average Profit Margin is 3.08%. 100% of the industry peers have a better Profit Margin.
VS Industry

ROA (0.15%) VS Industry: 0% outperformed.

0.15
7.17

ROE (0.62%) VS Industry: 0% outperformed.

0.62
17.21

Profit Margin (0.5%) VS Industry: 0% outperformed.

0.50
10.18

Valuation

Valuation Rating

2

With a price book ratio of 0.22, KORI is valued rather cheaply.
When comparing the price book ratio of KORI to the average industry price book ratio of 0.94, KORI is valued rather cheaply. KORI is also cheaper than 100% of the companies listed in the same industry.
With a Price/Earnings Ratio of 39.13, KORI can be considered very expensive at the moment.

With a Price/Earning Ratio of 39.13, KORI is valued a higher than the industry average, which is at 17.60. 100% of the companies listed in the same industry are cheaper than KORI!
The Forward Price/Earnings Ratio of 25.24 indicates a quite expensive current valuation of KORI.
When comparing the Enterprise Value to EBITDA ratio of KORI to the average industry ratio of 8.72, KORI is valued more expensive than its industry peers.
VS Industry

Price/Earnings (39.13) VS Industry: 0% outperformed.

39.13
11.68

Price/Book (0.22) VS Industry: 100% outperformed.

3.09
0.22

Enterprise Value/ EBITDA (8.72) VS Industry: 40% outperformed.

11.29
3.62

Growth

Growth Rating

3

The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
Looking at the last year, KORI shows a small growth in Revenue. The Revenue has grown by 7.27% in the last year.
KORI shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 7.23% yearly.
Based on estimates for the next 5 years, KORI will show a small growth in Revenue. The Revenue will grow by 5.00% on average per year.

KORI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -77.10%.
The earnings per share for KORI have been decreasing by -36.91% on average. This is quite bad
KORI is expected to show a very negative growth in Earnings Per Share. In the coming 5 years, the EPS will decrease by -17.31% yearly.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-36.91% -46.73% -77.1% -69.88% -27.27% -17.31% N/A
Revenue7.23% 7.1% 7.27% 8.42% 7.06% 6.39% 5%

Health

Health Rating

1

The Piotroski-F score of KORI is 5.00. This is a neutral score and indicates average health and profitability for KORI.
A Current Ratio of 0.63 indicates that KORI may have some problems paying its short term obligations.
When comparing the Current Ratio of KORI to the average industry Current Ratio of 1.32, KORI is less able to pay its short term obligations than its industry peers. 86% of its industry peers have a better Current Ratio.
KORI has a Quick Ratio of 0.63. This is a bad value and indicates that KORI is not financially healthy enough and could expect problems in meeting its short term obligations.

Compared to an average industry Quick Ratio of 0.96, KORI is worse placed to pay its short term obligations than its industry peers.
KORI has one of the worst Debt to Equity ratios in its industry. 100% of its industry peers require less debt for financing their operations.
KORI has an Altman-Z score of 0.51. This is a bad value and indicates that KORI is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 1.83, KORI is in worse financial state than most of its industry peers. 100% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (1.96) VS Industry: 0% outperformed.

1.96
0.03

Quick Ratio (0.62) VS Industry: 28% outperformed.

0.19
2.44

Current Ratio (0.63) VS Industry: 14% outperformed.

0.19
3.05

Altman-Z (0.51) VS Industry: 0% outperformed.

0.51
5.40

Dividend

Dividend Rating

4

KORI's Dividend Yield is a higher than the S&P500 average which is at 2.71.
The dividend of KORI is nicely growing with an annual growth rate of 10.51%!
KORI has a Yearly Dividend Yield of 3.51%. Purely for dividend investing, there may be better candidates out there.

KORI's Dividend Yield is comparable with the industry average which is at 3.51.
KORI's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
262.13% of the earnings are spent on dividend by KORI. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (3.51%) VS Industry: 60% outperformed.

0.59
3.73

KORIAN

EPA:KORI (6/5/2023, 3:14:17 PM)

7.435

-0.02 (-0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap791.51M
Analysts82.86
Price Target12.22 (64.36%)
Dividend
Industry RankSector Rank
Dividend Yield 3.51%
Dividend Growth(5Y)10.51%
DP262.13%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)-4.63%
PT rev (3m)-45%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-78.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.02%
Valuation
Industry RankSector Rank
PE 39.13
Fwd PE 25.24
P/S 0.18
P/FCF 3.31
P/OCF 0.92
P/B 0.22
P/tB N/A
EV/EBITDA 8.72
EPS(TTM)0.19
EY2.56%
EPS(NY)0.29
Fwd EY3.96%
FCF(TTM)2.25
FCFY30.24%
OCF(TTM)8.09
OCFY108.85%
SpS41.69
BVpS33.25
TBVpS-18.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.15%
ROE 0.62%
ROIC 2.43%
ROICexc 2.59%
ROICexgc 5.16%
OM 7.54%
PM 0.5%
GM 92.07%
ROA(3y)0.36%
ROA(5y)0.75%
ROE(3y)1.49%
ROE(5y)2.76%
ROIC(3y)2.49%
ROIC(5y)3.01%
ROICexc(3y)2.74%
ROICexc(5y)3.27%
ROICexgc(3y)5.64%
ROICexgc(5y)8.21%
ROICexcg growth 3Y-10.64%
ROICexcg growth 5Y-22.21%
ROICexc growth 3Y-9.78%
ROICexc growth 5Y-10.81%
OM growth 3Y-8.77%
OM growth 5Y-3.82%
PM growth 3Y-46.1%
PM growth 5Y-37.51%
GM growth 3Y-0.1%
GM growth 5Y0.03%
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 1.96
Debt/FCF 34.46
Debt/EBITDA 8.67
Cap/Depr 100.82%
Profit Quality 1085.11%
Current Ratio 0.63
Quick Ratio 0.62
Altman-Z 0.51
F-Score5
WACC2.98%
ROIC/WACC1.73
Cap/Depr(3y)95.42%
Cap/Depr(5y)108.61%
Profit Quality(3y)708.02%
Profit Quality(5y)519.75%
Growth
EPS 1Y-77.1%
EPS 3Y-46.73%
EPS 5Y-36.91%
EPS growth Q2Q-85.96%
EPS Next Y-69.88%
EPS Next 2Y-27.27%
EPS Next 3Y-17.31%
EPS Next 5YN/A
Revenue growth 1Y7.27%
Revenue growth 3Y7.1%
Revenue growth 5Y7.23%
Revenue growth Q2Q6.66%
Revenue Next Year8.42%
Revenue Next 2Y7.06%
Revenue Next 3Y6.39%
Revenue Next 5Y5%
EBIT growth 1Y-17.06%
EBIT growth 3Y-2.29%
EBIT growth 5Y3.14%
EBIT Next Year160.05%
EBIT Next 3Y43.4%
EBIT Next 5Y25.83%
FCF growth 1Y-23.06%
FCF growth 3Y-18.33%
FCF growth 5Y4.03%
OCF growth 1Y2.56%
OCF growth 3Y4.01%
OCF growth 5Y17.47%
Fundamental Stock Screener Links
Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext